1
Clarke C, Howard R, Rossor M, et al., editors. Neurology: a Queen Square textbook. Second edition. Chichester, West Sussex, UK: : Wiley Blackwell 2016. https://onlinelibrary.wiley.com/doi/book/10.1002/9781118486160
2
McCarthy RA, Warrington EK. Cognitive neuropsychology: a clinical introduction. San Diego, California: : Academic Press, Inc 1990. http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=2909618430004761&institutionId=4761&customerId=4760
3
Rossor M, Growdon JH. The dementias 2. [Place of publication not identified]: : Butterworth Heinemann/Elsevier 2007. http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=2909618250004761&institutionId=4761&customerId=4760
4
Hodges JR. Cognitive assessment for clinicians. 3 ed. [Oxford]: : Oxford University Press 2017. http://dx.doi.org/10.1093/med/9780198749189.001.0001
5
Kandel ER, Schwartz JH, Jessell TM, et al., editors. Principles of neural science. Fifth edition. New York: : McGraw Hill Medical 2013. http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=2909605810004761&institutionId=4761&customerId=4760
6
Husain M. Oxford textbook of cognitive neurology and dementia. [Oxford]: : Oxford University Press 2016. http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=2909605720004761&institutionId=4761&customerId=4760
7
Alzheimer’s Facts and Figures Report | Alzheimer’s Association. https://www.alz.org/alzheimers-dementia/facts-figures
8
Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Molecular Medicine 2016;8:595–608. doi:10.15252/emmm.201606210
9
Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. The Lancet Neurology 2014;13:614–29. doi:10.1016/S1474-4422(14)70090-0
10
Loy CT, Schofield PR, Turner AM, et al. Genetics of dementia. The Lancet 2014;383:828–40. doi:10.1016/S0140-6736(13)60630-3
11
Karran E, Hardy J. Antiamyloid Therapy for Alzheimer’s Disease — Are We on the Right Road? New England Journal of Medicine 2014;370:377–8. doi:10.1056/NEJMe1313943
12
Johnson KA, Fox NC, Sperling RA, et al. Brain Imaging in Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine 2012;2:a006213–a006213. doi:10.1101/cshperspect.a006213
13
Ross CA, Aylward EH, Wild EJ, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nature Reviews Neurology 2014;10:204–16. doi:10.1038/nrneurol.2014.24
14
Bates GP, Dorsey R, Gusella JF, et al. Huntington disease. Nature Reviews Disease Primers Published Online First: 23 April 2015. doi:10.1038/nrdp.2015.5
15
Wild EJ, Tabrizi SJ. Therapies targeting DNA and RNA in Huntington’s disease. The Lancet Neurology 2017;16:837–47. doi:10.1016/S1474-4422(17)30280-6
16
Carroll JB, Bates GP, Steffan J, et al. Treating the whole body in Huntington’s disease. The Lancet Neurology 2015;14:1135–42. doi:10.1016/S1474-4422(15)00177-5
17
Tabrizi SJ, Scahill RI, Durr A, et al. Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACK-HD study: the 12-month longitudinal analysis. The Lancet Neurology 2011;10:31–42. doi:10.1016/S1474-4422(10)70276-3
18
Tabrizi SJ, Reilmann R, Roos RA, et al. Potential endpoints for clinical trials in premanifest and early Huntington’s disease in the TRACK-HD study: analysis of 24 month observational data. The Lancet Neurology 2012;11:42–53. doi:10.1016/S1474-4422(11)70263-0
19
Tabrizi SJ, Scahill RI, Owen G, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington’s disease in the TRACK-HD study: analysis of 36-month observational data. The Lancet Neurology 2013;12:637–49. doi:10.1016/S1474-4422(13)70088-7
20
Jones L, Houlden H, Tabrizi SJ. DNA repair in the trinucleotide repeat disorders. The Lancet Neurology 2017;16:88–96. doi:10.1016/S1474-4422(16)30350-7
21
Rossor M, Collinge J, Fox N, et al. Dementia and Cognitive Impairment. In: Clarke C, Howard R, Rossor M, et al., eds. Neurology. Chichester, UK: : John Wiley & Sons, Ltd 2016. 289–336. doi:10.1002/9781118486160.ch8
22
Rossor MN, Fox NC, Mummery CJ, et al. The diagnosis of young-onset dementia. The Lancet Neurology 2010;9:793–806. doi:10.1016/S1474-4422(10)70159-9
23
Schott JM, Fox NC, Rossor MN. Assessment and investigation of the cognitively impaired adult. In: Husain M, Schott JM, eds. Oxford Textbook of Cognitive Neurology and Dementia. Oxford University Press 2016. 221–30. doi:10.1093/med/9780199655946.003.0021
24
Green AJE. RT-QuIC: a new test for sporadic CJD. Practical Neurology Published Online First: 3 October 2018. doi:10.1136/practneurol-2018-001935
25
Collinge J. Mammalian prions and their wider relevance in neurodegenerative diseases. Nature 2016;539:217–26. doi:10.1038/nature20415
26
Mead S, Rudge P. CJD mimics and chameleons. Practical Neurology 2017;17:113–21. doi:10.1136/practneurol-2016-001571
27
Walker Z, Possin KL, Boeve BF, et al. Lewy body dementias. The Lancet 2015;386:1683–97. doi:10.1016/S0140-6736(15)00462-6
28
Halliday GM, Holton JL, Revesz T, et al. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathologica 2011;122:187–204. doi:10.1007/s00401-011-0852-9
29
Barker RA, Williams-Gray CH. Review: The spectrum of clinical features seen with alpha synuclein pathology. Neuropathology and Applied Neurobiology 2016;42:6–19. doi:10.1111/nan.12303
30
Bras J, Guerreiro R, Darwent L, et al. Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Human Molecular Genetics 2014;23:6139–46. doi:10.1093/hmg/ddu334
31
McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies. Neurology 2017;89:88–100. doi:10.1212/WNL.0000000000004058
32
Weil RS, Lashley TL, Bras J, et al. Current concepts and controversies in the pathogenesis of Parkinson’s disease dementia and Dementia with Lewy Bodies. F1000Research 2017;6. doi:10.12688/f1000research.11725.1
33
Woollacott IOC, Rohrer JD. The clinical spectrum of sporadic and familial forms of frontotemporal dementia. Journal of Neurochemistry 2016;138:6–31. doi:10.1111/jnc.13654
34
Gordon E, Rohrer JD, Fox NC. Advances in neuroimaging in frontotemporal dementia. Journal of Neurochemistry 2016;138:193–210. doi:10.1111/jnc.13656
35
Ahmed RM, Devenney EM, Irish M, et al. Neuronal network disintegration: common pathways linking neurodegenerative diseases. Journal of Neurology, Neurosurgery & Psychiatry 2016;87:1234–41. doi:10.1136/jnnp-2014-308350
36
Fletcher PD, Warren JD. Semantic Dementia: a specific network-opathy. Journal of Molecular Neuroscience 2011;45:629–36. doi:10.1007/s12031-011-9586-3
37
Goll JC, Crutch SJ, Loo JHY, et al. Non-verbal sound processing in the primary progressive aphasias. Brain 2010;133:272–85. doi:10.1093/brain/awp235
38
Goll JC, Ridgway GR, Crutch SJ, et al. Nonverbal sound processing in semantic dementia: A functional MRI study. NeuroImage 2012;61:170–80. doi:10.1016/j.neuroimage.2012.02.045
39
Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology 2011;76:1006–14. doi:10.1212/WNL.0b013e31821103e6
40
Grossman M. The non-fluent/agrammatic variant of primary progressive aphasia. The Lancet Neurology 2012;11:545–55. doi:10.1016/S1474-4422(12)70099-6
41
Leyton CE, Hodges JR, McLean CA, et al. Is the logopenic-variant of primary progressive aphasia a unitary disorder? Cortex 2015;67:122–33. doi:10.1016/j.cortex.2015.03.011
42
Marshall CR, Hardy CJD, Volkmer A, et al. Primary progressive aphasia: a clinical approach. Journal of Neurology 2018;265:1474–90. doi:10.1007/s00415-018-8762-6
43
Rohrer JD, Knight WD, Warren JE, et al. Word-finding difficulty: a clinical analysis of the progressive aphasias. Brain 2007;131:8–38. doi:10.1093/brain/awm251
44
Rohrer JD, Ridgway GR, Crutch SJ, et al. Progressive logopenic/phonological aphasia: Erosion of the language network. NeuroImage 2010;49:984–93. doi:10.1016/j.neuroimage.2009.08.002
45
Rohrer JD, Rossor MN, Warren JD. Syndromes of nonfluent primary progressive aphasia: A clinical and neurolinguistic analysis. Neurology 2010;75:603–10. doi:10.1212/WNL.0b013e3181ed9c6b
46
Rohrer JD, Sauter D, Scott S, et al. Receptive prosody in nonfluent primary progressive aphasias. Cortex 2012;48:308–16. doi:10.1016/j.cortex.2010.09.004
47
Warren JD, Rohrer JD, Rossor MN. Frontotemporal dementia. BMJ 2013;347:f4827–f4827. doi:10.1136/bmj.f4827
48
Lynch DS, Rodrigues Brandão de Paiva A, Zhang WJ, et al. Clinical and genetic characterization of leukoencephalopathies in adults. Brain 2017;140:1204–11. doi:10.1093/brain/awx045
49
Hollak CEM, Lachmann R, editors. Inherited metabolic disease in adults: a clinical guide. [New York]: : Oxford University Press 2016. http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=3043210560004761&institutionId=4761&customerId=4760
50
Devenney E, Vucic S, Hodges JR, et al. Motor neuron disease-frontotemporal dementia: a clinical continuum. Expert Review of Neurotherapeutics 2015;15:509–22. doi:10.1586/14737175.2015.1034108
51
Strong MJ, Abrahams S, Goldstein LH, et al. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 2017;18:153–74. doi:10.1080/21678421.2016.1267768
52
Iranzo A, Fernández-Arcos A, Tolosa E, et al. Neurodegenerative Disorder Risk in Idiopathic REM Sleep Behavior Disorder: Study in 174 Patients. PLoS ONE 2014;9. doi:10.1371/journal.pone.0089741
53
Kielb SA, Ancoli-Israel S, Rebok GW, et al. Cognition in Obstructive Sleep Apnea-Hypopnea Syndrome (OSAS): Current Clinical Knowledge and the Impact of Treatment. NeuroMolecular Medicine 2012;14:180–93. doi:10.1007/s12017-012-8182-1
54
Mander BA, Winer JR, Jagust WJ, et al. Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pathology of Alzheimer’s Disease? Trends in Neurosciences 2016;39:552–66. doi:10.1016/j.tins.2016.05.002
55
McCarter SJ, St. Louis EK, Boeve BF. Sleep Disturbances in Frontotemporal Dementia. Current Neurology and Neuroscience Reports 2016;16. doi:10.1007/s11910-016-0680-3
56
Ooms S, Ju Y-E. Treatment of Sleep Disorders in Dementia. Current Treatment Options in Neurology 2016;18. doi:10.1007/s11940-016-0424-3
57
Hardy CJD, Marshall CR, Golden HL, et al. Hearing and dementia. Journal of Neurology 2016;263:2339–54. doi:10.1007/s00415-016-8208-y
58
Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. The Lancet 2017;390:2673–734. doi:10.1016/S0140-6736(17)31363-6
59
Goll JC, Crutch SJ, Warren JD. Central auditory disorders: toward a neuropsychology of auditory objects. Current Opinion in Neurology 2010;23:617–27. doi:10.1097/WCO.0b013e32834027f6
60
Husain M. Oxford textbook of cognitive neurology and dementia. [Oxford]: : Oxford University Press 2016. http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=3119511110004761&institutionId=4761&customerId=4760
61
Blennow K, Hardy J, Zetterberg H. The Neuropathology and Neurobiology of Traumatic Brain Injury. Neuron 2012;76:886–99. doi:10.1016/j.neuron.2012.11.021
62
Smith DH, Johnson VE, Stewart W. Chronic neuropathologies of single and repetitive TBI: substrates of dementia? Nature Reviews Neurology 2013;9:211–21. doi:10.1038/nrneurol.2013.29
63
McKee AC, Stein TD, Nowinski CJ, et al. The spectrum of disease in chronic traumatic encephalopathy. Brain 2013;136:43–64. doi:10.1093/brain/aws307
64
Fleminger S. Head injury as a risk factor for Alzheimer’s disease: the evidence 10 years on; a partial replication. Journal of Neurology, Neurosurgery & Psychiatry 2003;74:857–62. doi:10.1136/jnnp.74.7.857
65
Scott G, Ramlackhansingh AF, Edison P, et al. Amyloid pathology and axonal injury after brain trauma. Neurology 2016;86:821–8. doi:10.1212/WNL.0000000000002413
66
Hereditary and sporadic beta-amyloidoses. https://www.bioscience.org/2013/v18/af/4173/fulltext.htm
67
Johnson GVW. Tau phosphorylation in neuronal cell function and dysfunction. Journal of Cell Science 2004;117:5721–9. doi:10.1242/jcs.01558
68
Revesz T, Holton JL, Lashley T, et al. Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. Acta Neuropathologica 2009;118:115–30. doi:10.1007/s00401-009-0501-8
69
Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathologica 2012;123:1–11. doi:10.1007/s00401-011-0910-3
70
Thal DR. Neurodegeneration in Normal Brain Aging and Disease. Science of Aging Knowledge Environment 2004;2004:pe26–pe26. doi:10.1126/sageke.2004.23.pe26
71
Braak H, Braak E. Staging of alzheimer’s disease-related neurofibrillary changes. Neurobiology of Aging 1995;16:271–8. doi:10.1016/0197-4580(95)00021-6
72
Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 1991;41:479–479. doi:10.1212/WNL.41.4.479
73
Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathologica 2012;123:1–11. doi:10.1007/s00401-011-0910-3
74
Dobson R, Alvares D. The difficulties with vitamin B. Practical Neurology 2016;16:308–11. doi:10.1136/practneurol-2015-001344
75
Jonathan Carr. Neurosyphilis. Practical Neurology 2003;3:328–41.https://pn.bmj.com/content/3/6/328
76
Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. The Lancet Neurology 2016;15:391–404. doi:10.1016/S1474-4422(15)00401-9
77
Salvarani C, Brown RD, Hunder GG. Adult primary central nervous system vasculitis. The Lancet 2012;380:767–77. doi:10.1016/S0140-6736(12)60069-5
78
Halperin JJ, Kurlan R, Schwalb JM, et al. Practice guideline: Idiopathic normal pressure hydrocephalus: Response to shunting and predictors of response. Neurology 2015;85:2063–71. doi:10.1212/WNL.0000000000002193
79
Arash Asher. The effect of cancer treatment on cognitive function. undefinedhttps://www.semanticscholar.org/paper/The-effect-of-cancer-treatment-on-cognitive-Asher-Myers/6bdd550dab6cfad0714aa76dd2ee439ad983e4be
80
Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. The Lancet Neurology 2016;15:391–404. doi:10.1016/S1474-4422(15)00401-9
81
Cognitive Impairment Associated with Cancer: A Brief Review. Innovations in Clinical Neuroscience 2018;15.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819720/
82
Haddow LJ, Cartledge JD, Manji H. HIV and the brain: from AIDS to old age. Clinical Medicine 2013;13:s24–8. doi:10.7861/clinmedicine.13-6-s24
83
Nightingale S, Michael BD, Defres S, et al. Test them all; an easily diagnosed and readily treatable cause of dementia with life-threatening consequences if missed. Practical Neurology 2013;13:354–6. doi:10.1136/practneurol-2013-000689
84
HIV in the United Kingdom 2016 infographic. https://www.gov.uk/government/publications/hiv-in-the-united-kingdom
85
Itzhaki RF, Lathe R, Balin BJ, et al. Microbes and Alzheimer’s Disease. Journal of Alzheimer’s Disease 2016;51:979–84. doi:10.3233/JAD-160152
86
Nightingale S, Winston A, Letendre S, et al. Controversies in HIV-associated neurocognitive disorders. The Lancet Neurology 2014;13:1139–51. doi:10.1016/S1474-4422(14)70137-1
87
Richard W. Price and Bruce J. Brew. The AIDS Dementia Complex. The Journal of Infectious Diseases 1988;158.https://www.jstor.org/stable/30136610?seq=1#metadata_info_tab_contents
88
UK National Guidelines for HIV Testing 2008. https://www.bhiva.org/HIV-testing-guidelines
89
Zhou L, Miranda-Saksena M, Saksena NK. Viruses and neurodegeneration. Virology Journal 2013;10. doi:10.1186/1743-422X-10-172
90
De Chiara G, Marcocci ME, Sgarbanti R, et al. Infectious Agents and Neurodegeneration. Molecular Neurobiology 2012;46:614–38. doi:10.1007/s12035-012-8320-7
91
Wendorf KA, Winter K, Zipprich J, et al. Subacute Sclerosing Panencephalitis: The Devastating Measles Complication That Might Be More Common Than Previously Estimated. Clinical Infectious Diseases 2017;65:226–32. doi:10.1093/cid/cix302
92
Ghanem KG. REVIEW: Neurosyphilis: A Historical Perspective and Review. CNS Neuroscience & Therapeutics 2010;16:e157–68. doi:10.1111/j.1755-5949.2010.00183.x
93
Somasundaram O. Neuro syphilis: Portrayals by Sir Arthur Conan Doyle. Indian Journal of Psychiatry 2009;51. doi:10.4103/0019-5545.55103
94
Hachinski V, Iadecola C, Petersen RC, et al. National Institute of Neurological Disorders and Stroke–Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards. Stroke 2006;37:2220–41. doi:10.1161/01.STR.0000237236.88823.47
95
Gorelick PB, Scuteri A, Black SE, et al. Vascular Contributions to Cognitive Impairment and Dementia. Stroke 2011;42:2672–713. doi:10.1161/STR.0b013e3182299496
96
Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. The Lancet 2001;357:169–75. doi:10.1016/S0140-6736(00)03589-3
97
Leys D, Hénon H, Mackowiak-Cordoliani M-A, et al. Poststroke dementia. The Lancet Neurology 2005;4:752–9. doi:10.1016/S1474-4422(05)70221-0
98
O’Brien JT, Thomas A. Vascular dementia. The Lancet 2015;386:1698–706. doi:10.1016/S0140-6736(15)00463-8
